Additionally, BCR-ABL-positive malignant cell clones have been shown to persist within the CD34+ stem cell fractions, even in CML patients for whom imatinib had induced a complete cytogenetic remission [37]. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.